Antengene Announces NDA Submission for XPOVIO® in Indonesia

SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications (NDAs) for XPOVIO® (selinexor) to the Indonesia National Agency of Drug and Food...

Related Keywords

Thailand ,Malaysia ,Taiwan ,Shanghai ,China ,Australia ,Singapore ,South Korea ,Indonesia ,Hong Kong ,Peter Qian ,Jay Mei ,Asia Pacific ,Thomas Karalis ,Hong Kong Stock Exchange ,Indonesia National Agency Of Drug ,Karyopharm Therapeutics Inc ,Company Annual ,Antengene Corporation Limited ,New Drug Applications ,Indonesia National Agency ,Food Control ,Corporate Vice President ,Karyopharm Therapeutics ,Corporation Limited ,Patients Beyond ,Taiwan China ,Annual Report ,Hong Kong Stock ,